Lantern Pharma Inc. Research and Development Expense
Lantern Pharma Inc. (LTRN) reported Research and Development Expense of $1.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Lantern Pharma Inc. research and development expense for the quarter ending 2026-06-30 was $1.79M, a 41.64% decline year-over-year.
- Lantern Pharma Inc. research and development expense for the quarter ending 2026-03-31 was $1.72M, a 47.15% decline year-over-year.
- Lantern Pharma Inc. research and development expense for the quarter ending 2025-12-31 was $2.74M, a 35.71% decline year-over-year.
- Lantern Pharma Inc. research and development expense for the quarter ending 2025-09-30 was $2.44M, a 34.43% decline year-over-year.
- Lantern Pharma Inc. research and development expense for fiscal 2025 was $11.51M, a 28.60% decline from fiscal 2024.
- Lantern Pharma Inc. research and development expense for fiscal 2024 was $16.13M, a 35.57% increase from fiscal 2023.
- Lantern Pharma Inc. research and development expense for fiscal 2023 was $11.89M, a 38.26% increase from fiscal 2022.
- Lantern Pharma Inc. research and development expense for fiscal 2022 was $8.60M, a 13.64% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.79M 10-Q · filed 2026-08-14 | $3.52M 10-Q · filed 2026-08-14 | $6.26M derived: sum of 3 quarters · filed 2026-08-14 | $8.70M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $1.72M 10-Q · filed 2026-05-15 | $4.47M derived: sum of 2 quarters · filed 2026-05-15 | $6.91M derived: sum of 3 quarters · filed 2026-05-15 | $9.98M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.18M derived: sum of 2 quarters · filed 2026-03-30 | $8.25M derived: sum of 3 quarters · filed 2026-08-14 | $11.51M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $2.44M 10-Q · filed 2025-11-12 | $5.51M derived: sum of 2 quarters · filed 2026-08-14 | $8.77M 10-Q · filed 2025-11-12 | $13.04M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $3.07M 10-Q · filed 2026-08-14 | $6.33M 10-Q · filed 2026-08-14 | $10.60M derived: sum of 3 quarters · filed 2026-08-14 | $14.32M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $3.26M 10-Q · filed 2026-05-15 | $7.53M derived: sum of 2 quarters · filed 2026-05-15 | $11.25M derived: sum of 3 quarters · filed 2026-05-15 | $15.14M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $4.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $7.99M derived: sum of 2 quarters · filed 2026-03-30 | $11.87M derived: sum of 3 quarters · filed 2026-03-30 | $16.13M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $3.72M 10-Q · filed 2025-11-12 | $7.61M derived: sum of 2 quarters · filed 2025-11-12 | $11.86M 10-Q · filed 2025-11-12 | $15.43M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $3.89M 10-Q · filed 2025-08-13 | $8.14M 10-Q · filed 2025-08-13 | $11.71M derived: sum of 3 quarters · filed 2025-08-13 | $13.92M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $4.25M 10-Q · filed 2025-05-15 | $7.82M derived: sum of 2 quarters · filed 2025-05-15 | $10.03M derived: sum of 3 quarters · filed 2025-05-15 | $13.59M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $5.78M derived: sum of 2 quarters · filed 2025-03-27 | $9.34M derived: sum of 3 quarters · filed 2025-03-27 | $11.89M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $2.21M 10-Q · filed 2024-11-07 | $5.77M derived: sum of 2 quarters · filed 2024-11-07 | $8.32M 10-Q · filed 2024-11-07 | $10.57M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $3.56M 10-Q · filed 2024-08-08 | $6.11M 10-Q · filed 2024-08-08 | $8.36M derived: sum of 3 quarters · filed 2024-08-08 | $9.07M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $2.55M 10-Q · filed 2024-05-09 | $4.80M derived: sum of 2 quarters · filed 2024-05-09 | $5.51M derived: sum of 3 quarters · filed 2024-05-09 | $8.50M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $2.95M derived: sum of 2 quarters · filed 2024-03-18 | $5.94M derived: sum of 3 quarters · filed 2024-03-18 | $8.60M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $702.30K 10-Q · filed 2023-11-08 | $3.69M derived: sum of 2 quarters · filed 2023-11-08 | $6.35M 10-Q · filed 2023-11-08 | $8.51M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $2.99M 10-Q · filed 2023-08-09 | $5.65M 10-Q · filed 2023-08-09 | $7.81M derived: sum of 3 quarters · filed 2023-08-09 | $10.78M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $2.66M 10-Q · filed 2023-05-09 | $4.82M derived: sum of 2 quarters · filed 2023-05-09 | $7.79M derived: sum of 3 quarters · filed 2023-05-09 | $8.95M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $2.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $5.13M derived: sum of 2 quarters · filed 2023-03-20 | $6.29M derived: sum of 3 quarters · filed 2023-03-20 | $7.57M 10-K · filed 2023-03-20 | |
| 2021-09-30 | $2.96M 10-Q · filed 2022-11-07 | $4.13M derived: sum of 2 quarters · filed 2022-11-07 | $5.41M 10-Q · filed 2022-11-07 | $6.76M derived: sum of 4 quarters · filed 2022-11-07 | |
| 2021-06-30 | $1.16M 10-Q · filed 2022-08-08 | $2.44M 10-Q · filed 2022-08-08 | $3.79M derived: sum of 3 quarters · filed 2022-08-08 | $4.39M derived: sum of 4 quarters · filed 2022-08-08 | |
| 2021-03-31 | $1.28M 10-Q · filed 2022-05-03 | $2.63M derived: sum of 2 quarters · filed 2022-05-03 | $3.23M derived: sum of 3 quarters · filed 2022-05-03 | $3.39M derived: sum of 4 quarters · filed 2022-05-03 | |
| 2020-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.95M derived: sum of 2 quarters · filed 2022-03-10 | $2.11M derived: sum of 3 quarters · filed 2022-03-10 | $2.24M 10-K · filed 2022-03-10 | $10.00K 10-K · filed 2021-03-10 |
| 2020-09-30 | $600.77K 10-Q · filed 2021-11-01 | $757.79K derived: sum of 2 quarters · filed 2021-11-01 | $894.90K 10-Q · filed 2021-11-01 | ||
| 2020-06-30 | $157.02K 10-Q · filed 2021-07-29 | $294.13K 10-Q · filed 2021-07-29 | |||
| 2020-03-31 | $137.10K 10-Q · filed 2021-05-03 | ||||
| 2019-09-30 | $21.00K 10-Q · filed 2020-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |